脑脊液p-tau/Aβ42比值与脑FDG-PET或可可靠识别向AD转化的MCI「即将转化者」
该研究纳入77例连续MCI患者,诊断时完成神经系统/神经心理学评估、脑18F-FDG-PET及脑脊液分析,每6个月随访至少2年、最长8年。35例(45%)转化为AD痴呆,平均转化时间26.07个月;脑脊液p-tau/Aβ42是MCI向AD痴呆转化最准确的预测指标(灵敏度82.9%,特异度90%),且脑脊液p-tau/Aβ42与FDG-PET双阳性者转化显著早于仅脑脊液阳性者(中位转化时间17.1个月 vs 31.3个月)。
要点
- 77例MCI患者中35例(45%)转化为AD痴呆,平均转化时间26.07个月。
- 脑脊液p-tau/Aβ42预测MCI向AD痴呆转化:灵敏度82.9%,特异度90%。
- 脑脊液p-tau/Aβ42与FDG-PET双阳性者中位转化时间17.1个月,仅脑脊液阳性者31.3个月。
核心结论
- 脑脊液p-tau/Aβ42比值与脑FDG-PET或可预测MCI向全面AD痴呆的转化及其时间。
- 两种生物标志物均提示AD的MCI患者很可能短期内发展为AD痴呆,因而可能是需要短周期测试的新实验药物的理想靶人群。
研究设计与样本
- 纳入77例连续MCI患者,诊断时均有神经系统/神经心理学评估、脑18F-FDG-PET及脑脊液分析。
- 每6个月进行神经心理/神经科评估,中至长期随访(至少2年、最长8年)。
- 采用二项逻辑回归模型和Kaplan-Meier生存分析确定检测MCI向AD痴呆转化的最佳生物标志物或组合。
主要发现
- 77例MCI患者中35例(45%)转化为AD痴呆,自MCI诊断起平均转化时间26.07个月。
- 脑脊液p-tau/Aβ42是MCI向AD痴呆转化最准确的预测指标(灵敏度82.9%,特异度90%)。
- 脑脊液p-tau/Aβ42与FDG-PET双阳性的MCI患者转化为AD痴呆显著早于仅脑脊液阳性者(中位转化时间17.1个月 vs 31.3个月)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To know whether mild cognitive impairment (MCI) patients will develop Alzheimer's disease (AD) dementia in very short time or remain stable is of crucial importance, also considering new experimental drugs usually tested within very short time frames. Here we combined cerebrospinal fluid (CSF) AD biomarkers and a neurodegeneration marker such as brain FDG-PET to define an objective algorithm, suitable not only to reliably detect MCI converters to AD dementia but also to predict timing of conversion. METHODS: We included 77 consecutive MCI patients with neurological/neuropsychological assessment, brain 18F-FDG-PET and CSF analysis available at diagnosis and a neuropsychological/neurological evaluation every 6 months for a medium- to a long-term follow-up (at least 2 and up to 8 years). Binomial logistic regression models and Kaplan-Meier survival analyses were performed to determine the best biomarker (or combination of biomarkers) in detecting MCI converters to AD dementia and then, among the converters, those who converted in short time frames. RESULTS: Thirty-five out of 77 MCI patients (45%) converted to AD dementia, with an average conversion time since MCI diagnosis of 26.07 months. CSF p-tau/Aβ42 was the most accurate predictor of conversion from MCI to AD dementia (82.9% sensitivity; 90% specificity). CSF p-tau/Aβ42 and FDG-PET-positive MCIs converted to AD dementia significantly earlier than the CSF-positive-only MCIs (median conversion time, 17.1 vs 31.3 months). CONCLUSIONS: CSF p-tau/Aβ42 ratio and brain FDG-PET may predict both occurrence and timing of MCI conversion to full-blown AD dementia. MCI patients with both biomarkers suggestive for AD will likely develop an AD dementia shortly, thus representing the ideal target for any new experimental drug requiring short periods to be tested for.
引用
- Santangelo R, Masserini F, Agosta F, et al. CSF p-tau/Aβ42 ratio and brain FDG-PET may reliably detect MCI "imminent" converters to AD. Eur J Nucl Med Mol Imaging. 2020. PMID: 32415550. doi:10.1007/s00259-020-04853-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。